Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Bullboard - Stock Discussion Forum Jasper Therapeutics Inc JSPR

Healthcare Biotechnology

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk... see more

Add To Watchlist

Bullboard (NDAQ:JSPR)

View:

Post by whytestockson Oct 14, 2024 10:15am

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Stu

JUST IN: $JSPR Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria14 of 15 participants enrolled achieved a clinical response 10 of 12 ...more

Post by whytestockson Jun 14, 2024 3:30pm

Jasper Therapeutics Presents Data from Preclinical Briquilim

NEWS: $JSPR Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid CongressREDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc ...more

BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems

posted Oct 31, 2024 9:00am by BioVaxys Technology Corp.

"BioVaxys is at the forefront of a significant shift in the drug delivery landscape," James Passin, CEO of BioVaxys, stated, "These groundbreaking study results validate our strategic position in an important segment of the multi-billion drug delivery market. DPX not only outperforms current antigen delivery solutions but also demonstrate ...read more

Post by whytestockson Feb 07, 2024 4:45pm

Post by PressReleaseon Feb 17, 2023 8:20am

New Press Release - Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

(0)
•••

Post by PressReleaseon Feb 17, 2023 8:10am

New Press Release - Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days100% total donor chimerism was achieved through six months for the first patient and through three months for the second patientBoth patients are doing well post-transplant with...read article.

(0)
•••

Post by PressReleaseon Feb 17, 2023 8:00am

New Press Release - Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Oral Presentation, Abstract #59: 12 out of 12 AML in complete remission patients with full 1-year follow-up achieved successful neutrophil engraftment at a median of 19 days after conditioning with briquilimab in combination with fludarabine and low dose irradiation Oral Presentation...read article.

(0)
•••

Post by PressReleaseon Feb 16, 2023 4:05pm

New Press Release - Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients

Data Presented in Plenary Session at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR First two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-upThird sickle cell disease participant has now achieved 100% donor...read article.

(0)
•••

Post by PressReleaseon Feb 03, 2023 4:05pm

New Press Release - Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

(0)
•••

Post by PressReleaseon Jan 30, 2023 8:00am

New Press Release - Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023

REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

(0)
•••

Post by PressReleaseon Jan 27, 2023 1:10pm

New Press Release - Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

(0)
•••

Post by PressReleaseon Jan 25, 2023 8:00am

New Press Release - Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock

REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

(0)
•••

Post by PressReleaseon Jan 24, 2023 4:26pm

New Press Release - Jasper Therapeutics Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

< Previous

Next >

Dealroom for high-potential pre-IPO opportunities

Become a member today, It's free!

Bullboard - Stock Discussion Forum Jasper Therapeutics Inc JSPR

Bullboard (NDAQ:JSPR)

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Stu

Jasper Therapeutics Presents Data from Preclinical Briquilim

BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems

Jasper Therapeutics to Present at the Oppenheimer 34th Annua

Jasper Therapeutics to Present at the Oppenheimer 34th Annua

Jasper Therapeutics Announces Pricing of $50 Million Underwr

When (JSPR) Moves Investors should Listen

New Press Release - Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

New Press Release - Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

New Press Release - Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

New Press Release - Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients

New Press Release - Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

New Press Release - Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023

New Press Release - Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

New Press Release - Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock

New Press Release - Jasper Therapeutics Announces Proposed Public Offering of Common Stock

Featured News Links

Prospera Energy corporate update: 3 years of strategic restructuring, recovery and future growth

Discover Options Trading Strategies to Minimize your Tax Burden

Tribe Property Technologies Provides Update on Tribe Home, Demonstrating Increased Efficiencies with Property Management Platform

Learn how to Trade on the U.S. Election and other Economic and Environmental Events

Major Copper-Gold Discovery Revealed! High-Grade Rock Samples Signal Untapped Potential

Canadian Miner Launches Private Placement for Ambitious Alaskan Gold Project

Be a Part of a Gold Company Before it Catches the Attention of the Market’s Major Players

A Swedish Solution to Break European Dependency on China for Critical Raw Materials

Breakthrough in Cancer Vaccine Tech: New Platform Outshines Traditional Methods in Immune Activation

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard - Stock Discussion Forum Jasper Therapeutics Inc JSPR

Join the community and start posting on the bullboards today. It's free.

Create a portfolio watchlist today. It's free.

Bullboard (NDAQ:JSPR)

Featured News Links